Brief: 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis

89bio

14/05/2024 13:45

May 14 (Reuters) - 89Bio Inc  ETNB.O :
    * 89BIO INITIATES PHASE 3 ENLIGHTEN-CIRRHOSIS TRIAL OF
PEGOZAFERMIN IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
(MASH) PATIENTS WITH COMPENSATED CIRRHOSIS

Source text for Eikon:  ID:nGNX9ZJRyY 
Further company coverage:  ETNB.O 

 ((Reuters.Briefs@thomsonreuters.com;))